The objective of this study was to determine the effects of an LHRH-I antagonist, Cetrorelix, on human multiple myeloma (MM) cells and to elucidate the mechanisms of action. We demonstrated that LHRH-I and LHRHR-I genes were expressed in MM cell lines and primary Cetrorelix decreased the phosphorylation of ERK1/2 and STAT3 in myeloma cells, two crucial pathways for myeloma cells growth and survival. Moreover, the expression of p21 and p53 was increased, while the expression of anti-apoptotic proteins Bcl-2 and Bcl-XL was reduced by Cetrorelix. Our findings indicate that Cetrorelix induces cytotoxicity in myeloma cells through various mechanisms, and provide a rationale for investigating Cetrorelix for treatment of multiple myeloma.
Introduction
Multiple myeloma (MM) is the second most common hematological cancer in the United States, representing 10% of all hematopoietic malignancies (1) . MM is incurable, although novel approaches such as the proteasome inhibitor bortezomib have improved the treatment outcome (2) (3) . However, the majority of patients with refractory or relapsed disease show resistance to these therapies (4) (5) . Thus, the development of novel agents to treat MM remains an important task.
We observed in our gene array experiments that RPMI 8226 myeloma cells expressed the luteinizing hormone-releasing hormone LHRH-I and LHRHR-I, a finding which has not been reported previously (data not shown). Hypothalamic LHRH is the primary link between the brain and the pituitary in the regulation of gonadal functions, and plays a key role in control of vertebrate reproduction (6) . It has been shown that most vertebrate species express at least two forms of LHRH (7) . LHRH-I and its cognate receptor, LHRHR-I, have been also found in the human endometrium, placenta, breast, ovary, testis, and prostate (8) (9) (10) (11) (12) , as well as several malignant tumors and cell lines (10) .
In a number of human cancers, including endometrial, prostatic, colorectal, lung, and ovarian tumors, the proliferation of cancer cells can be inhibited by agonistic or antagonistic analogues of LHRH (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . Cetrorelix especially, a third generation LHRH antagonist, has been shown to induce apoptosis, growth inhibition, and cell cycle arrest of cancer cells (13, 16, 22) . Thus, Cetrorelix decreased the levels of cyclin A and Cdk2, but increased the level of p21 and p53 in trypsinization. Phospho-NF-кB p65 was tested using methods previously described (26) and cytokine quantification by qRT-PCR was described below.
RNA extraction, reverse transcription and PCR
Total cellular RNA was extracted and cDNA was synthesized as previously described (26) . Cells were treated as specified in the figure legends, collected, and caspase3 activity was evaluated by flow cytometry using methods previously described (26) .
Transient transfection of siRNA
The scrambled siRNA (siSCR) (catalogue no. sc-37007) and siRNA to knock down LHRHR-I (catalogue no. sc-4002) were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
RPMI 8226 cells were transfected with siRNA using the RNAiFect transfection system (Qiagen)
as reported (26) . Cells were incubated at 37°C for 40 hours before replating onto 12-well plates.
Cells were allowed to attach overnight (about 8 hours), then treated with Cetrorelix for 24 hours, followed by apoptosis analysis and Western blot.
Animal study
The pLenti7.3/V5-GFP/luciferase plasmid developed at our laboratory, along with packaging 
Statistical analysis
Statistical analysis was performed with the SPSS 11.5 (Chicago, IL) using t test or one way analysis of variance (ANOVA). In addition, Cetrorelix also significantly decreased the expression of mRNA for IL-6, VEGF-A, and BSF3 in BMSC. Since LHRH pathway has been shown to induce activation of NF-кB (32) and many of these cytokines expression are regulated by NF-кB pathway (33-34) we further examined the effect of Cetrorelix on NF-кB activity in the MM coculture system. The phosphorylation of p65 (RelA), an indicator for NF-кB activation, was significantly decreased after 6 hours Cetrorelix treatment in both MM cells and BMSCs (left and right panel respectively, Figure 5C ). This suggests that the decreased NF-кB activity and the decreased expression of these cytokines which are important for myeloma cell growth and survival may play a role in Cetrorelix-induced cytotoxicity and growth inhibition. Our findings suggest that the cell cycle regulatory genes, p53 and p21, play significant roles in Cetrorelix-induced growth inhibition. P53 is known to induce cell cycle arrest and apoptosis.
P21 is an inhibitor of cyclin-dependent kinases and plays a critical role in controlling the cell cycle. It is known that p21 can be up-regulated by both p53-dependent and p53-independent pathways (22) . In our study, the expression of p53 protein was increased in association with the increase of p21 protein, suggesting that Cetrorelix-induced upregulation of p21 may be mediated by p53. Although RPMI 8226 is regarded as a mutant p53-expressing cell line, RPMI 8226 cells still produce small amounts of wild type p53 with correct conformation (44-45). 
